Discovery Laboratories has chosen W. Thomas Amick as its next CEO. Amick has been interim CEO since August 2009. Last year, the FDA rejected Discovery's application for Surfaxin as a treatment for an infant respiratory ailment, questioning the test's ability to check on the quality changes that could occur over the course of the drug's shelf life. The developer hopes to file a complete response letter in early 2011. Discovery Labs release